|
1
|
Choi JH, Wong AS, Huang HF and Leung PC:
Gonadotropins and ovarian cancer. Endocr Rev. 28:440–461. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choi KC, Kang SK, Tai CJ, Auersperg N and
Leung PC: Follicle-stimulating hormone activates mitogen-activated
protein kinase in preneoplastic and neoplastic ovarian surface
epithelial cells. J Clin Endocrinol Metab. 87:2245–2253. 2002.
View Article : Google Scholar
|
|
3
|
Huang Y, Jin H, Liu Y, et al: FSH inhibits
ovarian cancer cell apoptosis by up-regulating survivin and
down-regulating PDCD6 and DR5. Endocr Relat Cancer. 18:13–26. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang Y, Hua K, Zhou X, et al: Activation
of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in
ovarian serous cystadenocarcinoma. Cell Res. 18:780–791. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ryan BM, Konecny GE, Kahlert S, et al:
Survivin expression in breast cancer predicts clinical outcome and
is associated with HER2, VEGF, urokinase plasminogen activator and
PAI-1. Ann Oncol. 17:597–604. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cai X, Ma S, Gu M, Zu C, Qu W and Zheng X:
Survivin regulates the expression of VEGF-C in lymphatic metastasis
of breast cancer. Diagn Pathol. 7:522012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mertens-Talcott SU, Chintharlapalli S, Li
X and Safe S: The oncogenic microRNA-27a targets genes that
regulate specificity protein transcription factors and the G2-M
checkpoint in MDA-MB-231 breast cancer cells. Cancer Res.
67:11001–11011. 2007. View Article : Google Scholar
|
|
8
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gagan J, Dey BK, Layer R, Yan Z and Dutta
A: MicroRNA-378 targets the myogenic repressor MyoR during myoblast
differentiation. J Biol Chem. 286:19431–19438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Naguibneva I, Ameyar-Zazoua M, Polesskaya
A, et al: The microRNA miR-181 targets the homeobox protein Hox-A11
during mammalian myoblast differentiation. Nat Cell Biol.
8:278–284. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugatani T and Hruska KA: MicroRNA-223 is
a key factor in osteoclast differentiation. J Cell Biochem.
101:996–999. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishi H, Ono K, Horie T, et al:
MicroRNA-27a regulates beta cardiac myosin heavy chain gene
expression by targeting thyroid hormone receptor beta1 in neonatal
rat ventricular myocytes. Mol Cell Biol. 31:744–755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Mertens-Talcott SU, Zhang S, Kim K,
Ball J and Safe S: MicroRNA-27a indirectly regulates estrogen
receptor {alpha} expression and hormone responsiveness in MCF-7
breast cancer cells. Endocrinology. 151:2462–2473. 2010.PubMed/NCBI
|
|
16
|
Wang J, Luo F, Lu JJ, Chen PK, Liu P and
Zheng W: VEGF expression and enhanced production by gonadotropins
in ovarian epithelial tumors. Int J Cancer. 97:163–167. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liao H, Zhou Q, Gu Y, Duan T and Feng Y:
Luteinizing hormone facilitates angiogenesis in ovarian epithelial
tumor cells and metformin inhibits the effect through the mTOR
signaling pathway. Oncol Rep. 27:1873–1878. 2012.PubMed/NCBI
|
|
18
|
Wong C, Wellman TL and Lounsbury KM: VEGF
and HIF-1alpha expression are increased in advanced stages of
epithelial ovarian cancer. Gynecol Oncol. 91:513–517. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gallo O, Franchi A, Magnelli L, et al:
Cyclooxygenase-2 pathway correlates with VEGF expression in head
and neck cancer. Implications for tumor angiogenesis and
metastasis. Neoplasia. 3:53–61. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim MH, Seo SS, Song YS, et al: Expression
of cyclooxygenase-1 and -2 associated with expression of VEGF in
primary cervical cancer and at metastatic lymph nodes. Gynecol
Oncol. 90:83–90. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marrogi AJ, Travis WD, Welsh JA, et al:
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial
growth factor in the angiogenesis of non-small cell lung carcinoma.
Clin Cancer Res. 6:4739–4744. 2000.PubMed/NCBI
|
|
22
|
Shtivelband MI, Juneja HS, Lee S and Wu
KK: Aspirin and salicylate inhibit colon cancer medium- and
VEGF-induced endothelial tube formation: correlation with
suppression of cyclooxygenase-2 expression. J Thromb Haemost.
1:2225–2233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang J, Ji J, Yuan F, et al:
Cyclooxygenase-2 expression is associated with VEGF-C and lymph
node metastases in gastric cancer patients. Biomed Pharmacother.
59(Suppl 2): S285–S288. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li ZM, Hu S, Xiao L, et al: Expression of
microRNA 27a and its correlation with drug resistance in human
ovarian cancer A2780/Taxol cells. Zhonghua Fu Chan Ke Za Zhi.
45:372–375. 2010.(In Chinese).
|
|
25
|
Chintharlapalli S, Papineni S, Abdelrahim
M, et al: Oncogenic microRNA-27a is a target for anticancer agent
methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon
cancer cells. Int J Cancer. 125:1965–1974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Philipsen S and Suske G: A tale of three
fingers: the family of mammalian Sp/XKLF transcription factors.
Nucleic Acids Res. 27:2991–3000. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bouwman P and Philipsen S: Regulation of
the activity of Sp1-related transcription factors. Mol Cell
Endocrinol. 195:27–38. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Safe S and Abdelrahim M: Sp transcription
factor family and its role in cancer. Eur J Cancer. 41:2438–2448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lou Z, O’Reilly S, Liang H, Maher VM,
Sleight SD and McCormick JJ: Down-regulation of overexpressed sp1
protein in human fibrosarcoma cell lines inhibits tumor formation.
Cancer Res. 65:1007–1017. 2005.PubMed/NCBI
|
|
30
|
Wang L, Wei D, Huang S, et al:
Transcription factor Sp1 expression is a significant predictor of
survival in human gastric cancer. Clin Cancer Res. 9:6371–6380.
2003.PubMed/NCBI
|
|
31
|
Zhang J, Zhu ZG, Ji J, et al:
Transcription factor Sp1 expression in gastric cancer and its
relationship to long-term prognosis. World J Gastroenterol.
11:2213–2217. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yao JC, Wang L, Wei D, et al: Association
between expression of transcription factor Sp1 and increased
vascular endothelial growth factor expression, advanced stage, and
poor survival in patients with resected gastric cancer. Clin Cancer
Res. 10:4109–4117. 2004. View Article : Google Scholar
|
|
33
|
Akiyama H, Tanaka T, Maeno T, et al:
Induction of VEGF gene expression by retinoic acid through
Sp1-binding sites in retinoblastoma Y79 cells. Invest Ophthalmol
Vis Sci. 43:1367–1374. 2002.PubMed/NCBI
|
|
34
|
Bermudez Y, Yang H, Saunders BO, Cheng JQ,
Nicosia SV and Kruk PA: VEGF- and LPA-induced telomerase in human
ovarian cancer cells is Sp1-dependent. Gynecol Oncol. 106:526–537.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cho SG, Yi Z, Pang X, et al:
Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor
angiogenesis by suppressing Sp1-mediated VEGF expression and
FAK/Rho GTPase activation. Cancer Res. 69:7062–7070. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li ZY, Zhu F, Hu JL, et al: Sp1
inhibition-mediated upregulation of VEGF 165 b induced by
rh-endostatin enhances antiangiogenic and anticancer effect of
rh-endostatin in A549. Tumour Biol. 32:677–687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Loeffler S, Fayard B, Weis J and
Weissenberger J: Interleukin-6 induces transcriptional activation
of vascular endothelial growth factor (VEGF) in astrocytes in vivo
and regulates VEGF promoter activity in glioblastoma cells via
direct interaction between STAT3 and Sp1. Int J Cancer.
115:202–213. 2005. View Article : Google Scholar
|
|
38
|
Novak EM, Metzger M, Chammas R, et al:
Downregulation of TNF-alpha and VEGF expression by Sp1 decoy
oligodeoxynucleotides in mouse melanoma tumor. Gene Ther.
10:1992–1997. 2003. View Article : Google Scholar : PubMed/NCBI
|
